Wall Street brokerages expect BioLife Solutions Inc (NASDAQ:BLFS) to report $0.01 earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have made estimates for BioLife Solutions’ earnings. The lowest EPS estimate is ($0.01) and the highest is $0.03. BioLife Solutions reported earnings of $0.05 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 80%. The firm is scheduled to announce its next earnings results on Thursday, November 14th.
According to Zacks, analysts expect that BioLife Solutions will report full year earnings of $0.08 per share for the current year, with EPS estimates ranging from $0.03 to $0.13. For the next year, analysts anticipate that the firm will report earnings of $0.29 per share, with EPS estimates ranging from $0.26 to $0.30. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover BioLife Solutions.
BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. BioLife Solutions had a net margin of 14.60% and a return on equity of 8.65%. The business had revenue of $6.70 million during the quarter, compared to the consensus estimate of $6.59 million.
NASDAQ:BLFS traded down $0.35 during trading hours on Tuesday, reaching $16.54. The company had a trading volume of 85,237 shares, compared to its average volume of 176,329. The company has a current ratio of 9.42, a quick ratio of 7.71 and a debt-to-equity ratio of 0.02. BioLife Solutions has a 52 week low of $9.15 and a 52 week high of $22.44. The firm has a market cap of $337.77 million, a price-to-earnings ratio of 118.14 and a beta of 1.35. The firm’s 50 day moving average price is $17.84 and its 200-day moving average price is $17.77.
In other news, VP James Mathers sold 2,500 shares of BioLife Solutions stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $19.71, for a total transaction of $49,275.00. Following the transaction, the vice president now owns 19,884 shares in the company, valued at approximately $391,913.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Todd Berard sold 3,000 shares of BioLife Solutions stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $17.97, for a total transaction of $53,910.00. Following the transaction, the vice president now owns 44,074 shares in the company, valued at approximately $792,009.78. The disclosure for this sale can be found here. Insiders have sold a total of 230,056 shares of company stock worth $4,370,349 in the last quarter. Corporate insiders own 27.00% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Marshall Wace LLP boosted its holdings in shares of BioLife Solutions by 210.0% during the 1st quarter. Marshall Wace LLP now owns 30,278 shares of the medical equipment provider’s stock valued at $542,000 after acquiring an additional 20,512 shares in the last quarter. FMR LLC acquired a new position in BioLife Solutions during the 1st quarter worth about $2,684,000. WINTON GROUP Ltd lifted its holdings in BioLife Solutions by 26.3% during the 2nd quarter. WINTON GROUP Ltd now owns 22,118 shares of the medical equipment provider’s stock worth $375,000 after buying an additional 4,607 shares during the period. Penbrook Management LLC acquired a new position in BioLife Solutions during the 2nd quarter worth about $493,000. Finally, Roubaix Capital LLC lifted its holdings in BioLife Solutions by 165.9% during the 2nd quarter. Roubaix Capital LLC now owns 120,313 shares of the medical equipment provider’s stock worth $2,039,000 after buying an additional 75,068 shares during the period. Institutional investors and hedge funds own 45.05% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
See Also: What is the Bid-Ask Spread?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.